文献速递心力衰竭与心肌病冠心病

单细胞分析与反向虚拟筛选预测达格列净治疗糖尿病心肌病血管内皮新靶点

[Integrating single-cell analysis and epharmalib reverse virtual screening to predict novel vascular endothelial cell targets of dapagliflozin in treating diabetic cardiomyopathy].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2025-01-01

本研究整合ePharmaLib反向虚拟筛选(15 148个蛋白晶体)、db/db小鼠心脏单细胞RNA测序(PRJNA1069235)及高脂饮食达格列净干预小鼠心脏芯片数据,鉴定达格列净潜在内皮靶点;体外用人脐静脉内皮细胞验证,高浓度达格列净可降低TNF-α诱导的炎症因子及多个差异基因表达。

要点

  • DCM小鼠心脏毛细血管内皮细胞丰度显著降低,微脉管和静脉内皮细胞丰度显著升高(P均<0.05)。
  • 反向虚拟筛选识别168个达格列净结合人源蛋白,与单细胞数据交集得15个差异基因。
  • 高浓度达格列净可降低TNF-α刺激HUVEC的IL-6、IL-1β、p-P65及多个差异基因表达(P均<0.05)。

核心结论

  • 达格列净可能通过调节Dlg1、Bcl2、Nos3、Pde7a和Nampt等关键基因,抑制内皮细胞炎症反应,改善糖尿病心肌病血管内皮功能障碍。

研究设计与样本

  • 对15 148个蛋白晶体行ePharmaLib反向虚拟筛选,分析人源蛋白与达格列净的结合关系。
  • 整合野生型与db/db小鼠心脏单细胞RNA测序数据(PRJNA1069235),行降维聚类鉴定内皮细胞亚群。
  • 用Agilent Mouse ceRNA Microarray芯片分析高脂饮食及达格列净干预小鼠心脏转录组。
  • 体外用人脐静脉内皮细胞分空白对照、TNF-α及达格列净低/中/高浓度组,检测炎症因子和差异基因表达。

主要发现

  • ePharmaLib反向虚拟筛选识别168个人源蛋白与达格列净有潜在结合关系。
  • 单细胞分析鉴定6种内皮细胞亚群;DCM组毛细血管内皮细胞丰度显著低,微脉管和静脉内皮细胞丰度显著高(P均<0.05)。
  • 细胞间通讯分析显示Pgf-Vegfr1受体配体对显著表达。
  • 单细胞数据与虚拟筛选交集识别15个差异表达基因,包括Bcl2、Baz2b、Nos3、Ephb4、Cdk8、Pparg、Pde2a、Fgfr2、Fto、Stk24、Dlg1、Gsk3b、Pdpk1、Fas和Tnks2。
  • 芯片数据与虚拟筛选交集获得Pde7a、Dlg1、Gsk3b、Nampt、Met和Adk共6个差异基因。

关键数值与推荐

  • 体外与TNF-α组相比,达格列净高浓度组(TNF-α 10 mg/L+达格列净10 μmol/L)HUVEC的IL-6、IL-1β和p-P65蛋白及Bcl2、Nos3、Cdk8、Pde2a、Dlg1、Pdpk1、Tnks2、Baz2b、Pparg、Fas、Pde7a和Nampt的mRNA表达水平显著低(P均<0.05)。

临床怎么用

  • 达格列净可能通过调控Dlg1、Bcl2、Nos3、Pde7a和Nampt等基因抑制内皮炎症,为DCM内皮功能障碍提供候选靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate endothelial cell heterogeneity in diabetic cardiomyopathy (DCM) and identify potential therapeutic targets of dapagliflozin in cardiac vascular endothelial cells. Methods: ePharmaLib reverse virtual screening was performed on 15 148 protein crystals to identified the binding interactions between human-derived proteins and dapagliflozin. Subsequently, single-cell RNA sequencing data (PRJNA1069235) from wild-type mice (control group) and db/db mice (DCM group) were integrated, then dimensionality reduction and clustering analysis were performed to identify endothelial cell subpopulations in the heart tissue of DCM mice, followed by functional annotation. Cell-cell communication analysis was explored to investigate fibroblast-endothelial cell interactions. The Agilent Mouse ceRNA Microarray chip was used to perform transcriptomic analysis of heart tissue from mice fed a high-fat diet and treated with dapagliflozin. Intersection analysis of reverse virtual screening results, single-cell RNA sequencing results and chip analysis data was performed to identify common differentially expressed genes. In vitro, human umbilical vein endothelial cells were divided into blank control group, tumor necrosis factor-α (TNF-α) group (TNF-α 10 mg/L), dapagliflozin low concentration group (TNF-α 10 mg/L+dagliazin 2 μmol/L), dapagliflozin medium concentration group (TNF-α 10 mg/L+dagliazin 5 μmol/L) and dapagliflozin high concentration group (TNF-α 10+dagliazin 10 μmol/L). Western blot and real-time reverse transcriptase polymerase chain reaction were used to detect the expression of inflammatory factors and differential genes. Results: ePharmaLib reverse virtual screening identified 168 human-derived proteins with potential binding affinity to dapagliflozin, and single-cell analysis identifiedf 6 types of endothelial cell subpopulations. Compared with the control group, the abundance of capillary endothelial cells was significantly lower in DCM group, while the abundance of microvascular and venous endothelial cells was significantly higher (P all<0.05). Cell-cell communication analysis showed significant expression of Pgf-Vegfr1 ligand-receptor pair. In addition, 15 differentially expressed genes were identified by intersection analysis of 168 dapagliflozin-binding proteins. Including Bcl2, Baz2b, Nos3, Ephb4, Cdk8, Pparg, Pde2a, Fgfr2, Fto, Stk24, Dlg1, Gsk3b, Pdpk1, Fas and Tnks2. Notably, Baz2b, Pparg, Fto and Gsk3b were differentially expressed in all cell subpopulations. Six differential genes, including Pde7a, Dlg1, Gsk3b, Nampt, Met and Adk, were obtained by the intersection of the chip analysis data with the virtual screening results of dapagliflozin. In vitro, compared to the human umbilical vein endothelial cells of TNF-α group, the expression levels of interleukin-6, interleukin-1β and p-P65 proteins and messenger RNA of Bcl2, Nos3, Cdk8, Pde2a, Dlg1, Pdpk1, Tnks2, Baz2b, Pparg, Fas, Pde7a and Nampt were significantly lower than dapagliflozin high concentration group (P all<0.05). Conclusions: Dapagliflozin may inhibit endothelial cell inflammatory responses and improve endothelial dysfunction in DCM by regulating key genes such as Dlg1, Bcl2, Nos3, Pde7a and Nampt. 目的: 探讨内皮细胞在糖尿病心肌病中的异质性,揭示达格列净对心脏血管内皮细胞的潜在作用靶点。 方法: 通过ePharmaLib反向虚拟筛选,对15 148个蛋白晶体进行分析,对人源蛋白与达格列净的结合关系进行筛选。随后,整合来自野生型小鼠(对照组)和db/db小鼠(糖尿病心肌病组)的单细胞RNA测序数据(PRJNA1069235),采用降维和聚类分析,鉴定糖尿病心肌病小鼠心脏组织中的内皮细胞亚群,并对其功能进行分析。采用细胞间通讯探讨成纤维细胞与内皮细胞的相互作用。使用Agilent Mouse ceRNA Microarray芯片对高脂饮食喂养和达格列净干预的小鼠心脏组织进行转录组分析。并对反向虚拟筛选结果、单细胞RNA测序结果和芯片分析数据进行交集分析,鉴定出共同的差异表达基因。细胞实验中,使用人脐静脉内皮细胞,分为空白对照组、肿瘤坏死因子-α(TNF-α)组(TNF-α 10 mg/L)、达格列净低浓度组(TNF-α 10 mg/L+达格列净2 μmol/L)、达格列净中浓度组(TNF-α 10 mg/L+达格列净5 μmol/L)和达格列净高浓度组(TNF-α 10 mg/L+达格列净10 μmol/L),采用Western blot法和实时反转录聚合酶链反应检测炎症因子和差异基因的表达。 结果: ePharmaLib反向虚拟筛选共筛选出168个人源蛋白与达格列净的结合关系,单细胞分析共鉴定出6种内皮细胞亚群,与对照组小鼠相比,糖尿病心肌病组小鼠毛细血管内皮细胞的丰度显著低,而微脉管和静脉内皮细胞的丰度显著高(P均<0.05)。细胞间通讯分析显示,Pgf-Vegfr1受体配体显著表达。此外,单细胞RNA测序结果与达格列净虚拟筛选结果的交集分析共识别出15个差异表达基因,包括Bcl2、Baz2b、Nos3、Ephb4、Cdk8、Pparg、Pde2a、Fgfr2、Fto、Stk24、Dlg1、Gsk3b、Pdpk1、Fas和Tnks2,其中Baz2b、Pparg、Fto、Dlg1和Gsk3b在各细胞亚群中均存在差异表达。芯片分析数据与达格列净虚拟筛选结果交集获得6个差异基因,包括Pde7a、Dlg1、Gsk3b、Nampt、Met和Adk。细胞实验显示,与TNF-α组相比,高浓度达格列净组人脐静脉内皮细胞中的白细胞介素-6、白细胞介素-1β和p-P65蛋白及Bcl2、Nos3、Cdk8、Pde2a、Dlg1、Pdpk1、Tnks2、Baz2b、Pparg、Fas、Pde7a和Nampt的信使RNA表达水平显著低(P均<0.05)。 结论: 达格列净通过调节Dlg1、Bcl2、Nos3、Pde7a和Nampt等关键基因表达,抑制内皮细胞炎症反应,可能改善糖尿病心肌病中血管内皮功能障碍。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Yang XQ, Na K, Yan CH, et al. [Integrating single-cell analysis and epharmalib reverse virtual screening to predict novel vascular endothelial cell targets of dapagliflozin in treating diabetic cardiomyopathy]. Zhonghua Xin Xue Guan Bing Za Zhi. 2025. PMID: 40528600. doi:10.3760/cma.j.cn112148-20250213-00102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。